Exporting antibodies from human cells to humanity.
Location: United States
Employees: 1-10
Total raised: $87M
Founded date: 2022
Investors 3
| Date | Name | Website |
| 16.12.2022 | Playground... | playground... |
| 27.12.2022 | Playground... | playground... |
| 24.07.2025 | Axial VC | axialvc.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.08.2026 | Series A | $75M | Playground... |
| 06.12.2022 | Seed | $12M | - |
Mentions in press and media 10
| Date | Title | Description |
| 16.08.2026 | Infinimmune Secures $75M to Propel Human Antibody Therapeutics | Infinimmune secures $75 million in Series A funding. This capital fuels the company's human-first antibody pipeline. Lead candidates target atopic dermatitis. Clinical trials for these programs are expected in 2027. Regeneron Ventures and P... |
| 12.08.2026 | River AI Secures $1.1B: Pioneering Personal AI and Open Intelligence | River AI secured $1.1 billion. The funding fuels its ambitious vision. Ex-xAI co-founder Igor Babuschkin leads the company. River aims to transform AI ownership. It seeks intelligence for users, not just labs. Its platform, the River API, e... |
| 12.08.2026 | Infinimmune Raises $75M in Series A Funding | Infinimmune, an Alameda, CA-based biotechnology company developing antibody therapeutics derived directly from the human immune system, raised $75M in Series A funding. The round was co-led by Regeneron Ventures and Playground Global with p... |
| 11.08.2026 | River AI Raises $1.1B to Expand Custom AI Platform | River AI Raises $1.1B for Open AI Expansion River AI has raised $1.1 billion in funding to expand its full-stack artificial intelligence platform. General Catalyst and AMP PBC led the round with strategic backing from NVIDIA and AMD Venture... |
| 11.08.2026 | Infinimmune Raises $75 Million Series A To Advance Human-Derived Antibody Pipeline | Infinimmune has raised $75 million in Series A financing to advance a pipeline of fully human antibody therapeutics for atopic dermatitis and other inflammatory diseases. The round was co-led by Regeneron Ventures and Playground Global, wit... |
| 11.08.2026 | Infinimmune Raises $75M To Advance Human Antibody Pipeline | Infinimmune Raises $75M For Clinical Development Infinimmune has raised $75 million in Series A funding to advance its antibody therapeutics pipeline. The financing was co-led by Regeneron Ventures and Playground Global. Several new and exi... |
| 06.12.2022 | Infinimmune Raises $12-Million Seed Funding to Design Drugs Using Human-Sourced Antibodies | - |
| 06.12.2022 | Infinimmune Raises $12M in Seed Funding | Infinimmune, a San Francisco, CA-based biotechnology company, raised $12M in Seed funding. The round was led by Playground Global, with participation from Pear VC, Civilization Ventures, Axial VC, Ron Alfa, Jacob Becraft, Paul Conley, and J... |
| - | Infinimmune | “Infinimmune” |
| - | Infinimmune | “Derived from human biology, engineered for human health. Infinimmune systematically surfaces and engineers the rare antibodies evolution has already proven in people and advances them into the clinic.” |